article Open AccessTop 1% cited
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Diabetologia · 2016 · Vol. 60(3) · pp. 568–573
Antonius Baartscheer(Academic Medical Center)Cees A. Schumacher(Academic Medical Center)Rob C. I. Wüst(Academic Medical Center)Jan W.T. Fiolet(University of Amsterdam)Ger J.M. Stienen(Amsterdam UMC Location VUmc)Ruben Coronel(University of Amsterdam)Coert J. Zuurbier✉(Academic Medical Center)
Abstract
The glucose lowering kidney-targeted agent, EMPA, demonstrates direct cardiac effects by lowering myocardial [Na<sup>+</sup>]<sub>c</sub> and [Ca<sup>2+</sup>]<sub>c</sub> and enhancing [Ca<sup>2+</sup>]<sub>m</sub>, through impairment of myocardial NHE flux, independent of SGLT2 activity.
Diabetes Treatment and ManagementPancreatic function and diabetesIon Transport and Channel RegulationEmpagliflozinEMPAInternal medicineEndocrinologyExtracellularChemistrySodiumSodium–hydrogen antiporterType 2 diabetesMedicine
MeSH terms
AnimalsBenzhydryl CompoundsCalciumCytoplasmDiabetes Mellitus, Type 2GlucosidesHypoglycemic AgentsMyocardiumRabbitsSodiumSodium-Hydrogen ExchangersMyocytes, CardiacRats
Citations
634
FWCI
32.95
field-weighted impact
References
17
Percentile
100%
vs. same field & year
Citations per year
Cited by
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Diabetologia · 2018 · 925 citations
References
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine · 2015 · 11,756 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.